Blood-camouflaged nanoparticles defeat drug-resistant breast tumors in mouse model

Дата публикации: 21-08-2026 13:40:03

Triple-negative breast cancer (TNBC) is one of the most aggressive and treatment-resistant subtypes of breast cancer, accounting for 15% to 20% of all cases. Unlike other breast cancers, TNBC lacks targetable receptors, leaving patients dependent largely on chemotherapy, with limited treatment options.

Основное содержимое страницы с новостью.

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	This new antibody may stop one of the deadliest breast cancers	0	8.13	23-01-2026
2	أدوية جديدة تحل محل العلاج الكيميائي لسرطان الثدي العدواني	5	7	25-06-2026
3	When Not to Push the Boulder	0	5	02-07-2026
4	Neoadjuvant Immune Checkpoint Inhibitors in Early Breast Cancer	0	7.64	01-10-2024
5	FDA Approves Datopotamab Deruxtecan-dlnk for Unresectable or Metastatic TNBC	5	7	24-06-2026
6	New study reveals how blood cancers outsmart BTK-targeted therapies	0	8.1	28-07-2026
7	Anticancer 'nanoswitch' technology shows promise in animal model of triple-negative breast cancer, colorectal cancer	5	7	10-07-2026
8	Smart nanoparticles light up brain cancer and destroy what surgery misses	0	10.41	27-08-2026
9	PARP Inhibitors for Breast Cancer Treatment	0	5.63	01-05-2024

Классификация: Наука. Схожих патентов: 0. Схожих новостей: 9. Тональность: 0. Информативность: 17.59. Источник: phys.org.